1
|
Prasch H, Wolfsgruber A, Thonhofer M, Culum A, Mandl C, Weber P, Zündel M, Nasseri SA, Gonzalez Santana A, Tegl G, Nidetzky B, Gruber K, Stütz AE, Withers SG, Wrodnigg TM. Ligand-Directed Chemistry on Glycoside Hydrolases - A Proof of Concept Study. Chembiochem 2023; 24:e202300480. [PMID: 37715738 DOI: 10.1002/cbic.202300480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 09/11/2023] [Accepted: 09/14/2023] [Indexed: 09/18/2023]
Abstract
Selective covalent labelling of enzymes using small molecule probes has advanced the scopes of protein profiling. The covalent bond formation to a specific target is the key step of activity-based protein profiling (ABPP), a method which has become an indispensable tool for measuring enzyme activity in complex matrices. With respect to carbohydrate processing enzymes, strategies for ABPP so far involve labelling the active site of the enzyme, which results in permanent loss of activity. Here, we report in a proof of concept study the use of ligand-directed chemistry (LDC) for labelling glycoside hydrolases near - but not in - the active site. During the labelling process, the competitive inhibitor is cleaved from the probe, departs the active site and the enzyme maintains its catalytic activity. To this end, we designed a building block synthetic concept for small molecule probes containing iminosugar-based reversible inhibitors for labelling of two model β-glucosidases. The results indicate that the LDC approach can be adaptable for covalent proximity labelling of glycoside hydrolases.
Collapse
Affiliation(s)
- Herwig Prasch
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - Andreas Wolfsgruber
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - Martin Thonhofer
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - André Culum
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - Christoph Mandl
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - Patrick Weber
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - Melanie Zündel
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - Seyed A Nasseri
- University of British Columbia, Department of Chemistry, 2036 Main Mall, Vancouver, BC, V6T 1Z1, Canada
| | - Andres Gonzalez Santana
- University of British Columbia, Department of Chemistry, 2036 Main Mall, Vancouver, BC, V6T 1Z1, Canada
| | - Gregor Tegl
- Graz University of Technology, Institute of Biotechnology and Biochemical Engineering, Petersgasse 10-12/I, 8010, Graz, Austria
| | - Bernd Nidetzky
- Graz University of Technology, Institute of Biotechnology and Biochemical Engineering, Petersgasse 10-12/I, 8010, Graz, Austria
| | - Karl Gruber
- University of Graz, Institute of Molecular Bioscience, Humboldtstraße 50/III, 8010, Graz, Austria
| | - Arnold E Stütz
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| | - Stephen G Withers
- University of British Columbia, Department of Chemistry, 2036 Main Mall, Vancouver, BC, V6T 1Z1, Canada
| | - Tanja M Wrodnigg
- Graz University of Technology, Institute of Chemistry and Technology of Biobased Systems, Stremayrgasse 9, 8010, Graz, Austria
| |
Collapse
|
2
|
Hang Z, Cai S, Lei T, Zhang X, Xiao Z, Wang D, Li Y, Bi W, Yang Y, Deng S, Wang L, Li Q, Du H. Transfer of Tumor-Bearing Mice Intestinal Flora Can Ameliorate Cognition in Alzheimer's Disease Mice. J Alzheimers Dis 2022; 86:1287-1300. [PMID: 35180124 DOI: 10.3233/jad-215495] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Fecal microbiota transplant (FMT) is a potential treatment approach for many diseases. Alzheimer's disease (AD) and cancer have been proven to have a specific antagonistic relationship to FMT. OBJECTIVE This article aims to explore whether intestinal flora transplantation from cancer individuals can ameliorate cognitive impairment. METHODS Morris water maze and object recognition tests were performed to assess cognitive function after the fecal flora from tumor-bearing and WT mice were transplanted into AD mice by gavage. The effect of flora transplantation on AD was analyzed by thioflavin T staining, western blot, and 16S RNA sequencing. RESULTS AD mice with FMT significantly improved short-term memory level and cognitive ability compared with Tg + NaCl group. Inflammatory factors in the plasma were regulated, and Aβ plaques burden in the hippocampus and cortex were decreased. FMT in the tumor-bearing group showed a higher significant amelioration in symptoms compared to the healthy group. 16S RNA sequencing revealed that FMT treatments could reverse the increased Firmicutes and Prevotella and the decreased Bacteroidetes, Bacteroides, and Sutterella in AD mice. AD mice transplanted with tumor-bearing mice feces additionally increased the density of Oscillospira, Odoribacter, and AF12. Furthermore, the predicted functional analyses showed that the metabolism of inorganic and organic salts in the intestinal flora of AD mice was also reversed by FMT. CONCLUSION Intestinal flora transplantation from tumor-bearing mice can ameliorate the cognitive impairment of AD mice.
Collapse
Affiliation(s)
- Zhongci Hang
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Shanglin Cai
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Tong Lei
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Xiaoshuang Zhang
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Zhuangzhuang Xiao
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Donghui Wang
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Yingxian Li
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China
| | - Wangyu Bi
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Yanjie Yang
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Shiwen Deng
- School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Li Wang
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| | - Quanhai Li
- Cell Therapy Laboratory, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.,Department of Immunology, Basic Medical College, Hebei Medical University, Shijiazhuang, Hebei, China
| | - Hongwu Du
- Daxing Research Institute, University of Science and Technology Beijing, Beijing, China.,School of Chemistry and Biological Engineering, University of Science and Technology Beijing, Beijing, China
| |
Collapse
|
3
|
Duong TH, Paramita Devi A, Tran NMA, Phan HVT, Huynh NV, Sichaem J, Tran HD, Alam M, Nguyen TP, Nguyen HH, Chavasiri W, Nguyen TC. Synthesis, α-glucosidase inhibition, and molecular docking studies of novel N-substituted hydrazide derivatives of atranorin as antidiabetic agents. Bioorg Med Chem Lett 2020; 30:127359. [PMID: 32738998 DOI: 10.1016/j.bmcl.2020.127359] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Revised: 05/25/2020] [Accepted: 06/17/2020] [Indexed: 01/11/2023]
Abstract
A series of novel N-substituted hydrazide derivatives were synthesized by reacting atranorin, a compound with a natural depside structure (1), with a range of hydrazines. The natural product and 12 new analogues (2-13) were investigated for inhibition of α-glucosidase. The N-substituted hydrazide derivatives showed more potent inhibition than the original. The experimental results were confirmed by docking analysis. This study suggests that these compounds are promising molecules for diabetes therapy. Molecular dynamics simulations were carried out with compound 2 demonstrating the best docking model using Gromac during simulation up to 20 ns to explore the stability of the complex ligand-protein. Furthermore, the activity of all synthetic compounds 2-13 against a normal cell line HEK293, used for assessing their cytotoxicity, was evaluated.
Collapse
Affiliation(s)
- Thuc-Huy Duong
- Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, Viet Nam; Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City, Viet Nam.
| | - Asshaima Paramita Devi
- Center of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand
| | | | - Hoang-Vinh-Truong Phan
- Department of Chemistry, Ho Chi Minh City University of Education, 280 An Duong Vuong Street, District 5, 748342 Ho Chi Minh City, Viet Nam
| | - Ngoc-Vinh Huynh
- Department of Organic Chemistry, VNUHCM - University of Science, Ho Chi Minh City, Viet Nam
| | - Jirapast Sichaem
- Research Unit in Natural Products Chemistry and Bioactivities, Faculty of Science and Technology, Thammasat University Lampang Campus, Lampang 52190, Thailand.
| | - Hoai-Duc Tran
- Industrial University of Ho Chi Minh, Ho Chi Minh City, Viet Nam
| | - Mahboob Alam
- Division of Chemistry and Biotechnology, Dongguk University, 123 Dongdae-ro, Gyeongju 780-714, Republic of Korea
| | - Thi-Phuong Nguyen
- NTT Hi-Tech Institute, Nguyen Tat Thanh University, 300A Nguyen Tat Thanh, District 4, Ho Chi Minh City, Viet Nam
| | - Huu-Hung Nguyen
- Faculty of Technology, Van Lang University, 45 Nguyen Khac Nhu, District 1, Ho Chi Minh City, Viet Nam
| | - Warinthorn Chavasiri
- Center of Excellence in Natural Products Chemistry, Department of Chemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand
| | - Tien-Cong Nguyen
- Department of Chemistry, Ho Chi Minh City University of Education, 280 An Duong Vuong Street, District 5, 748342 Ho Chi Minh City, Viet Nam.
| |
Collapse
|
4
|
Xiao Y, Chen X, Huang S, Li G, Mo M, Zhang L, Chen C, Guo W, Zhou M, Wu Z, Cen L, Long S, Li S, Yang X, Qu S, Pei Z, Xu P. Iron promotes α-synuclein aggregation and transmission by inhibiting TFEB-mediated autophagosome-lysosome fusion. J Neurochem 2018; 145:34-50. [PMID: 29364516 DOI: 10.1111/jnc.14312] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 01/15/2018] [Accepted: 01/17/2018] [Indexed: 12/21/2022]
Affiliation(s)
- Yousheng Xiao
- Department of Neurology; The First Affiliated Hospital of Guangxi Medical University; Nanning China
- Department of Neurology; National Key Clinical; Department and Key Discipline of Neurology; The First Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - Xiang Chen
- Department of Neurology; National Key Clinical; Department and Key Discipline of Neurology; The First Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - Shuxuan Huang
- Department of Neurology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - Guihua Li
- Department of Neurology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - Mingshu Mo
- Department of Neurology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - Li Zhang
- Geriatric Neurology Department; Nanjing Brain Hospital; Nanjing Medical University; Nanjing China
| | - Chaojun Chen
- Department of Neurology; Guangzhou Chinese Medical Integrated Hospital (Huadu); Guangzhou China
| | - Wenyuan Guo
- Department of Neurology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - Miaomiao Zhou
- Department of Neurology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - Zhuohua Wu
- Department of Neurology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| | - Luan Cen
- Department of Neurology; The First Affiliated Hospital of Guangxi Medical University; Nanning China
| | - Simei Long
- Department of Neurology; National Key Clinical; Department and Key Discipline of Neurology; The First Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - Shaomin Li
- Ann Romney Center for Neurologic Disease; Brigham and Women's Hospital; Harvard Medical School; Boston MA USA
| | - Xinling Yang
- Department of Neurology; The Second Affiliated Hospital of Xinjiang Medical University; Urumqi China
| | - Shaogang Qu
- Clinical Medicine Research Center; Shunde Hospital; Southern Medical University; Foshan China
| | - Zhong Pei
- Department of Neurology; National Key Clinical; Department and Key Discipline of Neurology; The First Affiliated Hospital of Sun Yat-sen University; Guangzhou China
| | - Pingyi Xu
- Department of Neurology; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
- Key Laboratory of Respiratory Disease; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou China
| |
Collapse
|
5
|
Lysosomal Re-acidification Prevents Lysosphingolipid-Induced Lysosomal Impairment and Cellular Toxicity. PLoS Biol 2016; 14:e1002583. [PMID: 27977664 PMCID: PMC5169359 DOI: 10.1371/journal.pbio.1002583] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Accepted: 11/11/2016] [Indexed: 12/20/2022] Open
Abstract
Neurodegenerative lysosomal storage disorders (LSDs) are severe and untreatable, and mechanisms underlying cellular dysfunction are poorly understood. We found that toxic lipids relevant to three different LSDs disrupt multiple lysosomal and other cellular functions. Unbiased drug discovery revealed several structurally distinct protective compounds, approved for other uses, that prevent lysosomal and cellular toxicities of these lipids. Toxic lipids and protective agents show unexpected convergence on control of lysosomal pH and re-acidification as a critical component of toxicity and protection. In twitcher mice (a model of Krabbe disease [KD]), a central nervous system (CNS)-penetrant protective agent rescued myelin and oligodendrocyte (OL) progenitors, improved motor behavior, and extended lifespan. Our studies reveal shared principles relevant to several LSDs, in which diverse cellular and biochemical disruptions appear to be secondary to disruption of lysosomal pH regulation by specific lipids. These studies also provide novel protective strategies that confer therapeutic benefits in a mouse model of a severe LSD.
Collapse
|
6
|
Sánchez-Fernández EM, García Fernández JM, Mellet CO. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem Commun (Camb) 2016; 52:5497-515. [PMID: 27043200 DOI: 10.1039/c6cc01564f] [Citation(s) in RCA: 112] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Lysosomal storage disorders (LSDs) are often caused by mutations that destabilize native folding and impair the trafficking of enzymes, leading to premature endoplasmic reticulum (ER)-associated degradation, deficiencies of specific hydrolytic functions and aberrant storage of metabolites in the lysosomes. Enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) are available for a few of these conditions, but most remain orphan. A main difficulty is that virtually all LSDs involve neurological decline and neither proteins nor the current SRT drugs can cross the blood-brain barrier. Twenty years ago a new therapeutic paradigm better suited for neuropathic LSDs was launched, namely pharmacological chaperone (PC) therapy. PCs are small molecules capable of binding to the mutant protein at the ER, inducing proper folding, restoring trafficking and increasing enzyme activity and substrate processing in the lysosome. In many LSDs the mutated protein is a glycosidase and the accumulated substrate is an oligo- or polysaccharide or a glycoconjugate, e.g. a glycosphingolipid. Although it might appear counterintuitive, substrate analogues (glycomimetics) behaving as competitive glycosidase inhibitors are good candidates to perform PC tasks. The advancements in the knowledge of the molecular basis of LSDs, including enzyme structures, binding modes, trafficking pathways and substrate processing mechanisms, have been put forward to optimize PC selectivity and efficacy. Moreover, the chemical versatility of glycomimetics and the variety of structures at hand allow simultaneous optimization of chaperone and pharmacokinetic properties. In this Feature Article we review the advancements made in this field in the last few years and the future outlook through the lessons taught by three archetypical LSDs: Gaucher disease, GM1-gangliosidosis and Fabry disease.
Collapse
Affiliation(s)
- Elena M Sánchez-Fernández
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Profesor García González 1, 41012, Sevilla, Spain.
| | - José M García Fernández
- Instituto de Investigaciones Químicas (IIQ), CSIC - Universidad de Sevilla, Avda. Américo Vespucio 49, 41092 Sevilla, Spain.
| | - Carmen Ortiz Mellet
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, Profesor García González 1, 41012, Sevilla, Spain.
| |
Collapse
|
7
|
Horowitz M, Elstein D, Zimran A, Goker-Alpan O. New Directions in Gaucher Disease. Hum Mutat 2016; 37:1121-1136. [DOI: 10.1002/humu.23056] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2015] [Accepted: 07/20/2016] [Indexed: 12/17/2022]
Affiliation(s)
- Mia Horowitz
- Department of Cell Research and Immunology, Faculty of Life Sciences; Tel Aviv University; Ramat Aviv Israel
| | - Deborah Elstein
- Gaucher Clinic; Shaare Zedek Medical Center; Jerusalem Israel
| | - Ari Zimran
- Gaucher Clinic; Shaare Zedek Medical Center; Jerusalem Israel
| | | |
Collapse
|
8
|
Xu M, Motabar O, Ferrer M, Marugan JJ, Zheng W, Ottinger EA. Disease models for the development of therapies for lysosomal storage diseases. Ann N Y Acad Sci 2016; 1371:15-29. [PMID: 27144735 DOI: 10.1111/nyas.13052] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Revised: 03/02/2016] [Accepted: 03/02/2016] [Indexed: 12/11/2022]
Abstract
Lysosomal storage diseases (LSDs) are a group of rare diseases in which the function of the lysosome is disrupted by the accumulation of macromolecules. The complexity underlying the pathogenesis of LSDs and the small, often pediatric, population of patients make the development of therapies for these diseases challenging. Current treatments are only available for a small subset of LSDs and have not been effective at treating neurological symptoms. Disease-relevant cellular and animal models with high clinical predictability are critical for the discovery and development of new treatments for LSDs. In this paper, we review how LSD patient primary cells and induced pluripotent stem cell-derived cellular models are providing novel assay systems in which phenotypes are more similar to those of the human LSD physiology. Furthermore, larger animal disease models are providing additional tools for evaluation of the efficacy of drug candidates. Early predictors of efficacy and better understanding of disease biology can significantly affect the translational process by focusing efforts on those therapies with the higher probability of success, thus decreasing overall time and cost spent in clinical development and increasing the overall positive outcomes in clinical trials.
Collapse
Affiliation(s)
- Miao Xu
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland.,Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Omid Motabar
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland
| | - Marc Ferrer
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland
| | - Juan J Marugan
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland
| | - Wei Zheng
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland
| | - Elizabeth A Ottinger
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland
| |
Collapse
|
9
|
Rauch JN, Gestwicki JE. Rehabilitating mutant GCase. ACTA ACUST UNITED AC 2015; 21:919-20. [PMID: 25126987 DOI: 10.1016/j.chembiol.2014.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Gaucher's disease is a hereditary deficiency of the enzyme β-glucocerebrosidase (GCase) that is most commonly treated by enzyme replacement therapy. In this issue of Chemistry & Biology, Tan and colleagues search for alternative ways to rehabilitate mutant GCase by understanding how it interacts with the proteostasis network.
Collapse
Affiliation(s)
- Jennifer N Rauch
- Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Disease, University of California at San Francisco, 675 Nelson Rising Lane, San Francisco, CA 94158, USA
| | - Jason E Gestwicki
- Department of Pharmaceutical Chemistry, Institute for Neurodegenerative Disease, University of California at San Francisco, 675 Nelson Rising Lane, San Francisco, CA 94158, USA.
| |
Collapse
|
10
|
Castilla J, Rísquez R, Higaki K, Nanba E, Ohno K, Suzuki Y, Díaz Y, Ortiz Mellet C, García Fernández JM, Castillón S. Conformationally-locked N-glycosides: exploiting long-range non-glycone interactions in the design of pharmacological chaperones for Gaucher disease. Eur J Med Chem 2014; 90:258-66. [PMID: 25461326 DOI: 10.1016/j.ejmech.2014.11.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Revised: 10/13/2014] [Accepted: 11/01/2014] [Indexed: 11/16/2022]
Abstract
Pyranoid-type glycomimetics having a cis-1,2-fused glucopyranose-2-alkylsulfanyl-1,3-oxazoline (Glc-PSO) structure exhibit an unprecedented specificity as inhibitors of mammalian β-glucosidase. Notably, their inhibitory potency against human β-glucocerebrosidase (GCase) was found to be strongly dependent on the nature of aglycone-type moieties attached at the sulfur atom. In the particular case of ω-substituted hexadecyl chains, an amazing influence of the terminal group was observed. A comparative study on a series of Glc-PSO derivatives suggests that hydrogen bond acceptor functionalities, e.g. fluoro or methyloxycarbonyl, significantly stabilize the Glc-PSO:GCase complex. The S-(16-fluorohexadecyl)-PSO glycomimetic turned out to be a more potent GCase competitive inhibitor than ambroxol, a non glycomimetic drug currently in pilot trials as a pharmacological chaperone for Gaucher disease. Moreover, the inhibition constant increased by one order of magnitude when shifting from neutral (pH 7) to acidic (pH 5) media, a favorable characteristic for a chaperone candidate. Indeed, the fluoro-PSO derivative also proved superior to ambroxol in mutant GCase activity enhancement assays in N370S/N370S Gaucher fibroblasts. The results presented here represent a proof of concept of the potential of exploiting long-range non-glycone interactions for the optimization of glycosidase inhibitors with chaperone activity.
Collapse
Affiliation(s)
- Javier Castilla
- Department de Química Analítica i Química Orgànica, Universitat Rovira i Virgili, C/ Marcel·lí Domingo s/n, 43007 Tarragona, Spain
| | - Rocío Rísquez
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, C/ Profesor García González 1, 41012 Sevilla, Spain
| | - Katsumi Higaki
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan
| | - Eiji Nanba
- Division of Functional Genomics, Research Center for Bioscience and Technology, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan
| | | | - Yoshiyuki Suzuki
- Tokyo Metropolitan Institute of Medical Science, Tokyo 204-8588, Japan
| | - Yolanda Díaz
- Department de Química Analítica i Química Orgànica, Universitat Rovira i Virgili, C/ Marcel·lí Domingo s/n, 43007 Tarragona, Spain.
| | - Carmen Ortiz Mellet
- Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, C/ Profesor García González 1, 41012 Sevilla, Spain.
| | - José M García Fernández
- Instituto de Investigaciones Químicas (IIQ), CSIC - Universidad de Sevilla, C/ Américo Vespucio 49, Isla de la Cartuja, 41092 Sevilla, Spain
| | - Sergio Castillón
- Department de Química Analítica i Química Orgànica, Universitat Rovira i Virgili, C/ Marcel·lí Domingo s/n, 43007 Tarragona, Spain
| |
Collapse
|